Journal article
High expression of integrin αvβ3 enables uptake of targeted fluorescent probes into ovarian cancer cells and tumors
Bioorganic & medicinal chemistry, Vol.26(8), pp.2085-2091
05/01/2018
DOI: 10.1016/j.bmc.2018.03.007
PMCID: PMC5963687
PMID: 29548784
Abstract
The cell line OVCAR-4 was recently ranked as one of the most representative cell lines for high grade serous ovarian cancer (HGSOC). However, little work has been done to assess the susceptibility of OVCAR-4 cells and tumors to the more common types of molecular targeting. Proteome profiles suggest OVCAR-4 express high levels of integrin αvβ3 receptors. Using flow cytometry with fluorescent antibodies we determined that OVCAR-4 cells have high number of integrin αvβ3 receptors ([9.8 ± 2.5] × 10
/cell) compared to the well-characterized cell line U87-MG ([5.2 ± 1.4] × 10
/cell). However, OVCAR-4 cells also have roughly three times the surface area of U87-MG cells, so the average αvβ3 receptor density is actually lower (11 ± 3 versus 18 ± 6 receptors/µm
). A series of new fluorescent molecular probes was prepared with structures comprised of a deep-red squaraine fluorophore (∼680 nm emission) covalently attached to zero, one, or two cyclic pentapeptide cRGD sequences for integrin targeting. Microscopy studies showed that uptake of the divalent probe into cultured OVCAR-4 cells was 2.2 ± 0.4 higher than the monovalent probe, which in turn was 2.2 ± 0.4 higher than the untargeted probe. This probe targeting trend was also seen in OVCAR-4 mouse tumor models. The results suggest that clinically relevant OVCAR-4 cells can be targeted using molecular probes based on αvβ3 integrin receptor antagonists such as the cRGD peptide. Furthermore, deep-red fluorescent cRGD-squaraine probes have potential as targeted stains of cancerous tissue associated with HGSOC in surgery and pathology settings.
Details
- Title: Subtitle
- High expression of integrin αvβ3 enables uptake of targeted fluorescent probes into ovarian cancer cells and tumors
- Creators
- Scott K Shaw - University of Notre Dame, 236 Nieuwland Science Hall, Notre Dame, IN 46545, United StatesCynthia L Schreiber - University of Notre Dame, 236 Nieuwland Science Hall, Notre Dame, IN 46545, United StatesFelicia M Roland - University of Notre Dame, 236 Nieuwland Science Hall, Notre Dame, IN 46545, United StatesPaul M Battles - University of Notre Dame, 236 Nieuwland Science Hall, Notre Dame, IN 46545, United StatesSeamus P Brennan - University of Notre Dame, 236 Nieuwland Science Hall, Notre Dame, IN 46545, United StatesSimon J Padanilam - University of Notre Dame, 236 Nieuwland Science Hall, Notre Dame, IN 46545, United StatesBradley D Smith - University of Notre Dame, 236 Nieuwland Science Hall, Notre Dame, IN 46545, United States. Electronic address: author@university.edu
- Resource Type
- Journal article
- Publication Details
- Bioorganic & medicinal chemistry, Vol.26(8), pp.2085-2091
- DOI
- 10.1016/j.bmc.2018.03.007
- PMID
- 29548784
- PMCID
- PMC5963687
- NLM abbreviation
- Bioorg Med Chem
- ISSN
- 0968-0896
- eISSN
- 1464-3391
- Grant note
- R01 GM059078 / NIGMS NIH HHS T32 GM075762 / NIGMS NIH HHS
- Language
- English
- Date published
- 05/01/2018
- Academic Unit
- Chemistry
- Record Identifier
- 9984216600002771
Metrics
7 Record Views